MATCH Treatment Subprotocol Z1E: LOXO-101 in Patients with Tumors with NTRK Fusions
* Patients must have a malignancy harboring an NTRK1, NTRK2 or NTRK3 gene fusion, as determined by the MATCH screening assessment.
* Patients must not have known hypersensitivity to LOXO-101 or compounds of similar chemical or biologic composition.
* Patients with inability to discontinue treatment with a strong CYP3A4 inhibitor or inducer prior to start of treatment are excluded.
* Patients who have previously received treatment with a TRKA, TRKB, or TRKC inhibitor are excluded. Such inhibitors include LOXO-101, entrectinib (RXDX-101), TSR-011, DS6051, Altiratinib (DCC-2701), MGCD516, Dovitinib (TKI258, CHIR528), AZD7451, PLX7486, and BIBF1120.
Multiple Tumor Types
Alison Conlin, M.D.
ECOG (Eastern Cooperative Oncology Group)
The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.